Get started
Author

Chelsea L. Rahiman

Observed names: C. Rahiman, Chelsea Rahiman
OpenAlex ID: A5116036753
Targeting CD73-A 2a R-Mediated Adenosine Signaling at the Tumor-Immune Interface Overcomes Radioresistance
2026 · Shruti Bansal, Luis Aparicio, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract CT017: Neoadjuvant IL-1β and PD-1 inhibition in localized clear-cell renal cell carcinoma: Clinical and correlative analyses of the phase 1b SPARC-1 trial
2026 · Patrick J. McCann, Aleksandar Obradovic, et al. · Cancer Research
Abstract 2173: Development of novel syngeneic mouse models of mHSPC and mCRPC for evaluation of radiopharmaceuticals on the immune tumor microenvironment (TME).
2026 · Brian Ragaishis, Andrei Molotkov, et al. · Cancer Research
Trial in Progress: A Phase II Single-Arm Study Testing SBRT, Adenosine Signaling Modulation, and Immune Checkpoint Inhibition for Men with Hormone Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)
2025 · M. Patel, C. Rahiman, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Abstract 4699: Intratumoral adenosine: Contributions from host versus tumor and interaction with radiotherapy
2025 · Shruti Bansal, Samantha Sarti, et al. · Cancer Research
Abstract B028: Multimodal approach to characterization of metabolism and immune modulation with insights from spatial metabolomics and transcriptomics
2025 · Chelsea L. Rahiman, Roberto Ribas, et al. · Clinical Cancer Research
Abstract B011: Adenosine signaling and immune modulation in the tumor microenvironment: insights from lung cancer murine model of radiation therapy
2025 · Krishan K. Saini, Samanta Sarti, et al. · Clinical Cancer Research
Works count: 7
Citation count:
H-index:
I10-index:
Year
Topic
Type